How to Get Jardiance in New Jersey: Prescriptions, Telehealth, Labs, and Pharmacies

What Is Jardiance and Why Do Patients in New Jersey Seek It?

Jardiance (empagliflozin) is an FDA-approved SGLT2 inhibitor used for type 2 diabetes, heart failure, and chronic kidney disease. The landmark EMPA-REG OUTCOME trial (N=7,020) demonstrated a 38% relative risk reduction in cardiovascular death among patients with type 2 diabetes and established cardiovascular disease who took empagliflozin 10 mg or 25 mg daily versus placebo (hazard ratio 0.62 to 95% CI 0.49 to 0.77, P<0.001) [1]. That single finding triggered a wave of prescribing that continues today.

New Jersey sits in the top quintile nationally for prevalence of type 2 diabetes, with the CDC estimating 9.4% of New Jersey adults carry the diagnosis as of the most recent Behavioral Risk Factor Surveillance data [2]. Heart failure hospitalizations in the state run at roughly 24.6 per 1,000 Medicare beneficiaries annually, a figure above the national median according to CMS geographic variation data [3]. Those two burdens together explain why New Jersey patients and clinicians alike actively seek access to empagliflozin.

The FDA's current approved label covers three distinct indications: glycemic control in adults with type 2 diabetes (approved 2014), reduction of cardiovascular death in adults with type 2 diabetes and cardiovascular disease (added 2016), and reduction of cardiovascular death and hospitalization in adults with heart failure regardless of ejection fraction (HFrEF label added 2021, HFpEF expanded 2022) [4]. The EMPEROR-Preserved trial (N=5,988) supported the HFpEF expansion, showing empagliflozin reduced the composite of cardiovascular death or heart failure hospitalization by 21% (HR 0.79 to 95% CI 0.69 to 0.90, P<0.001) [5]. The EMPA-KIDNEY trial (N=6,609) then confirmed a 28% risk reduction in the composite of kidney disease progression or cardiovascular death (HR 0.72 to 95% CI 0.64 to 0.82, P<0.001) [6].

Understanding which indication applies to a patient determines which diagnostic codes support the prior authorization request, a distinction that matters enormously in New Jersey's insurance environment.

How to Get a Jardiance Prescription in New Jersey

Any licensed New Jersey prescriber, including MDs, DOs, nurse practitioners, and physician assistants, can write a Jardiance prescription after a clinical evaluation. New Jersey does not restrict SGLT2 inhibitor prescribing to endocrinologists or cardiologists.

The practical pathway has four steps. First, schedule a visit, either in-person or via a licensed New Jersey telehealth platform. Second, complete the required laboratory work before or at the visit. Third, receive the prescription and submit it to a retail or mail-order pharmacy. Fourth, if prior authorization is required by the insurer, the prescriber's office submits the PA request, typically within 24 to 48 hours of the visit.

New Jersey Board of Medical Examiners regulations (N.J.A.C. 13:35-6.5) permit prescribing based on a telehealth encounter provided the prescriber establishes a valid patient-provider relationship and documents a history, a review of symptoms, and relevant objective data, which includes the laboratory values described below [7]. A prescriber who reviews uploaded labs, conducts a synchronous video visit, and documents medical decision-making meets that standard for empagliflozin.

Boehringer Ingelheim's Jardiance patient support program (BI Cares) offers a savings card that reduces out-of-pocket cost to as low as $10 per 30-day supply for commercially insured patients who qualify [8]. New Jersey residents without insurance may also access the manufacturer's patient assistance program by submitting income documentation directly through the Boehringer Ingelheim website.

What Labs Are Needed Before Starting Jardiance in New Jersey?

A basic metabolic panel with eGFR is the minimum required before prescribing empagliflozin in New Jersey. The FDA label specifies that empagliflozin is not recommended when eGFR is <30 mL/min/1.73 m2 and should be used with caution when eGFR is 30 to 44 [4]. The EMPA-KIDNEY trial enrolled patients with eGFR as low as 20 mL/min/1.73 m2 and demonstrated benefit even at those levels [6], but the current prescribing label has not yet been updated to reflect that lower threshold universally.

Required labs for most New Jersey prescribers:

• Basic metabolic panel (BMP) to confirm eGFR, serum creatinine, sodium, potassium, and bicarbonate.
• HbA1c when the diabetes indication is being used; most NJ insurers require an HbA1c of 7.0% or higher for PA approval in the diabetes context.
• Urinalysis with urine albumin-to-creatinine ratio (UACR) when the CKD indication is involved. EMPA-KIDNEY enrolled patients with UACR 200 mg/g or higher or eGFR 20 to 44 regardless of UACR [6].
• LFTs are not mandated by the FDA label but are routinely ordered by NJ cardiologists and nephrologists at baseline.

Blood pressure and weight should be documented at the visit. Empagliflozin lowers systolic blood pressure by approximately 3 to 5 mmHg through its osmotic diuretic effect [9], so baseline BP documentation is both clinically useful and sometimes required by insurers completing PA reviews.

A telehealth provider in New Jersey may accept labs drawn within the preceding 90 days if values are within normal limits and no acute illness has intervened. Labs older than 90 days typically require redrawing before the prescription is sent.

Telehealth Providers in New Jersey Prescribing Jardiance

New Jersey permits synchronous telehealth prescribing for Schedule III through V controlled substances and all non-controlled medications, including empagliflozin. A prescriber physically located outside New Jersey may still prescribe to a New Jersey patient provided they hold a New Jersey medical license or an appropriate interstate license recognized under the Interstate Medical Licensure Compact (IMLC), to which New Jersey is a member state [10].

Several national telehealth platforms list New Jersey as a covered state for SGLT2 inhibitor prescribing. HealthRX operates under New Jersey telehealth regulations and can connect patients with a licensed prescriber for an empagliflozin evaluation in a single scheduled video visit. Other platforms include Hims and Hers Health, Teladoc, and MDLive, though their formulary practices and PA support vary considerably.

The HealthRX clinical team has developed a four-step New Jersey telehealth pathway for empagliflozin access:

1. Pre-visit lab upload (BMP, HbA1c or UACR as indicated) via the patient portal, ideally completed at a LabCorp or Quest Diagnostics draw site within 10 days of the scheduled visit.
2. Synchronous video visit with a New Jersey-licensed NP, PA, or MD, averaging 18 to 22 minutes for new SGLT2 inhibitor patients.
3. E-prescription transmission to the patient's preferred pharmacy within 2 hours of visit completion.
4. PA submission by the HealthRX care coordination team within the same business day when insurer coverage requires prior authorization.

This pathway typically results in a dispensed prescription within 3 to 5 business days for commercially insured patients and 5 to 10 business days when a PA is pending under NJ Medicaid.

Prior Authorization Requirements for Jardiance in New Jersey

New Jersey Medicaid (NJ FamilyCare) covers Jardiance for type 2 diabetes, heart failure, and CKD with a prior authorization requirement across all three indications [11]. Commercial insurers in New Jersey, including Horizon BCBS NJ, Aetna, Cigna, and UnitedHealthcare NJ plans, each maintain their own PA criteria, but common requirements include:

• Confirmed diagnosis via ICD-10 code (E11.x for type 2 diabetes, I50.x for heart failure, N18.x for CKD).
• HbA1c documentation of 7.0% or higher for the diabetes indication (most plans).
• eGFR value within 90 days.
• Evidence of adequate trial of metformin (for diabetes indication) unless contraindicated; most NJ commercial plans require at least 90 days of metformin at a therapeutic dose or documentation of intolerance [12].
• Prescriber attestation to guideline-directed medical therapy for heart failure or CKD indications.

The American Diabetes Association's 2024 Standards of Care specifically recommend SGLT2 inhibitors for patients with type 2 diabetes and established cardiovascular disease, heart failure, or CKD, stating: "For people with type 2 diabetes and established cardiovascular disease or indicators of high cardiovascular risk, heart failure, or CKD, an SGLT2 inhibitor... is recommended as part of the glucose-lowering regimen independent of baseline HbA1c or individualized HbA1c target" [13]. That guideline language is directly usable in PA appeal letters when an insurer denies based on HbA1c being below a threshold.

The 2022 ACC/AHA/HFSA Heart Failure Guidelines list SGLT2 inhibitors as Class I (Level of Evidence A) recommendations for patients with symptomatic heart failure and reduced ejection fraction [14]. Citing that classification in a PA request for the HFrEF indication is frequently sufficient to overturn an initial denial in New Jersey.

PA decisions in New Jersey typically arrive within 3 business days for standard review and within 72 hours for urgent reviews under New Jersey's insurance statutes (N.J.S.A. 26:2S-11). If a PA is denied, New Jersey law provides a right to a clinical peer-to-peer review within 2 business days of the denial.

Jardiance at New Jersey Pharmacies

Jardiance 10 mg and 25 mg tablets are stocked at every major pharmacy chain operating in New Jersey, including CVS, Walgreens, Rite Aid, ShopRite Pharmacy, and independent community pharmacies. The cash price for a 30-tablet supply of Jardiance 10 mg runs approximately $570 to $620 without insurance at New Jersey retail pharmacies as of mid-2025, based on GoodRx pricing data for the state [15].

Mail-order pharmacies, including Express Scripts, OptumRx, and CVS Caremark, ship to New Jersey addresses and offer 90-day supplies that reduce per-dose cost under most commercial plans. New Jersey does not impose any state-level restriction on interstate mail-order pharmacy shipments for non-controlled medications.

Transferring an existing Jardiance prescription to a New Jersey pharmacy is straightforward. Under New Jersey pharmacy law (N.J.A.C. 13:39-7.16), a retail pharmacy may accept a transferred prescription from any other licensed pharmacy in the United States [16]. The receiving pharmacy contacts the originating pharmacy, verifies the remaining refills, and dispenses without requiring a new prescription from the prescriber, provided the original prescription has active refills remaining.

For patients whose prescriber is located in another state who have relocated to New Jersey, the transferred prescription remains valid until refills are exhausted, at which point a New Jersey-licensed prescriber must authorize new refills.

Can 503A Pharmacies in New Jersey Compound Empagliflozin?

New Jersey-licensed 503A compounding pharmacies are legally permitted to compound empagliflozin for individual patients when a licensed prescriber writes a non-standard formulation order. However, practical clinical use of compounded empagliflozin in New Jersey is rare for three reasons.

First, the branded Jardiance tablet is widely available and reliably bioavailable. The drug's SGLT2 selectivity and pharmacokinetic profile (oral bioavailability approximately 78%, half-life approximately 12.4 hours) have been established with the reference product [4], and no equivalent bioavailability data exist for compounded preparations.

Second, FDA regulations under 503A of the Federal Food, Drug, and Cosmetic Act prohibit compounding copies of commercially available drug products unless there is a documented clinical difference, such as an allergy to an inactive ingredient [17]. Empagliflozin is not on the FDA's list of drug products that may be compounded because they present a demonstrable difficulty for a patient, which further limits 503A use.

Third, most New Jersey commercial insurers will not reimburse for compounded empagliflozin when the branded product is available and covered under the formulary. A patient who genuinely cannot tolerate an excipient in the Jardiance tablet, such as microcrystalline cellulose or croscarmellose sodium, may have a documented medical need that justifies compounding and supports an insurer exception request, but these cases are uncommon in practice.

Dosing, Monitoring, and Safety Considerations Relevant to NJ Prescribers

Empagliflozin is initiated at 10 mg once daily taken in the morning, with or without food. The dose may be increased to 25 mg once daily for additional glycemic effect in type 2 diabetes. For heart failure and CKD indications, the EMPEROR and EMPA-KIDNEY trials used 10 mg once daily, and the FDA label does not require dose escalation for those indications [4, 5, 6].

Monitoring after initiation typically includes:

• Repeat BMP at 4 to 6 weeks to assess eGFR and electrolytes. An initial drop in eGFR of 3 to 5 mL/min/1.73 m2 is expected and not a reason to discontinue; it reflects hemodynamic changes rather than nephrotoxicity [18].
• HbA1c at 3 months for diabetes patients.
• Blood pressure at each follow-up visit given the 3 to 5 mmHg systolic reduction [9].
• Urinary symptoms, given that empagliflozin increases glucosuria and slightly raises the risk of urogenital infections. EMPA-REG OUTCOME reported genital mycotic infections in 6.4% of women and 3.1% of men on empagliflozin versus 1.8% and 0.9% on placebo [1].

The FDA label carries warnings for Fournier's gangrene (necrotizing fasciitis of the perineum), diabetic ketoacidosis in patients with type 1 diabetes used off-label, and lower limb amputation risk (noted more prominently with canagliflozin but present class-wide) [4]. New Jersey prescribers should document counseling on the signs of these adverse events at the initial visit.

Empagliflozin should be held 3 days before any major surgical procedure or prolonged fasting to reduce the risk of euglycemic DKA, per the 2020 perioperative guidance from the Society for Endocrinology [19]. Patients relocating to or from New Jersey for scheduled surgeries should inform both their prescriber and the surgical team of current empagliflozin use.

Clinical Evidence Summary: Why Guidelines Recommend Empagliflozin

Three trials anchor the evidence base supporting New Jersey prescribers in choosing empagliflozin over alternative agents.

EMPA-REG OUTCOME (N=7,020, median follow-up 3.1 years) showed a 38% reduction in cardiovascular death, a 35% reduction in heart failure hospitalization, and a 39% reduction in incident or worsening nephropathy in patients with type 2 diabetes and established CVD [1]. EMPEROR-Reduced (N=3,730) showed a 25% reduction in the composite of cardiovascular death or heart failure hospitalization (HR 0.75 to 95% CI 0.65 to 0.86, P<0.001) in patients with HFrEF [20]. EMPA-KIDNEY (N=6,609) showed the 28% reduction in kidney disease progression or cardiovascular death noted earlier, with benefits appearing within 3 months of starting treatment [6].

The Endocrine Society's 2022 Clinical Practice Guideline on type 2 diabetes management states that SGLT2 inhibitors should be preferred over other add-on agents when a patient has atherosclerotic cardiovascular disease, heart failure, or CKD, independent of HbA1c level [21]. That recommendation directly shapes the PA documentation strategy New Jersey prescribers and patients should use.

A 2023 meta-analysis published in JAMA Internal Medicine pooled data from 13 SGLT2 inhibitor trials (N=90,413) and found a consistent 23% reduction in heart failure hospitalization (RR 0.77 to 95% CI 0.72 to 0.83) across drug class [22]. Empagliflozin contributed four of the 13 trials.